How Do Peptides Work in the Body?

Peptides work by interacting with receptors — specialised proteins found on the surface of (or inside) cells. Think of it like a lock and key: each peptide has a specific 3D shape that fits certain receptors, and only those receptors.

When a peptide binds to its target receptor, it doesn't enter the cell directly. Instead, it triggers a conformational change in the receptor protein, which then relays the signal inward. This is called signal transduction.

Different peptides bind to different receptors, which is why they have such varied effects. GLP-1 receptor agonists like semaglutide bind to GLP-1 receptors in the pancreas and brain. BPC-157 interacts with growth factor receptors involved in tissue repair. CJC-1295 binds to growth hormone-releasing hormone (GHRH) receptors in the pituitary gland.

Key point: Peptides are highly selective. Unlike many small-molecule drugs that can interact with multiple targets (causing side effects), peptides tend to bind specifically to their intended receptor.

Once a peptide binds its receptor, it sets off a chain reaction inside the cell called a signalling cascade. This is how a tiny molecular event at the cell surface translates into a measurable biological effect.

Here's a simplified version of what happens:

• •Step 1: Peptide binds to receptor on cell surface
• •Step 2: Receptor changes shape and activates intracellular proteins (often G-proteins or kinases)
• •Step 3: These proteins activate further downstream messengers (like cAMP, calcium ions, or phosphorylation cascades)
• •Step 4: The cascade reaches the cell nucleus or other machinery, triggering gene expression, protein production, or metabolic changes

Example — GLP-1 signalling: When semaglutide binds the GLP-1 receptor on pancreatic beta cells, it activates adenylyl cyclase → increases cAMP → enhances insulin secretion. The same receptor in the brain's hypothalamus triggers satiety signals, reducing appetite.

Example — BPC-157 signalling: BPC-157 appears to upregulate growth factor receptors (VEGF, FGF) and modulate the nitric oxide system, promoting angiogenesis (new blood vessel formation) and accelerating tissue repair.

The specificity of these cascades is what makes peptides interesting to researchers — they can influence precise biological pathways without the broad systemic effects of many conventional drugs.

A peptide's half-life — how long it remains active in the body — determines how often it needs to be administered and how sustained its effects are.

Short half-life peptides (minutes to hours): - Natural GLP-1: ~2 minutes (rapidly degraded by DPP-4 enzymes) - GHRP-6: ~15–30 minutes - BPC-157: estimated 1–2 hours (limited human data)

Modified peptides with extended half-lives: - Semaglutide: ~7 days (fatty acid chain binds to albumin, shielding it from degradation) - CJC-1295 with DAC: ~6–8 days (Drug Affinity Complex binds to albumin) - Tirzepatide: ~5 days

Pharmaceutical researchers extend half-lives through several strategies: PEGylation (attaching polyethylene glycol chains), fatty acid acylation (semaglutide's approach), D-amino acid substitution (replacing natural L-amino acids with mirror-image versions that resist enzymatic breakdown), and cyclisation (forming ring structures that are harder for enzymes to cleave).

Bioavailability — the proportion of administered peptide that reaches systemic circulation — also varies by route. Subcutaneous injection typically achieves 65–95% bioavailability, while oral peptides face significant degradation in the GI tract (oral semaglutide uses an absorption enhancer called SNAC to achieve ~1% bioavailability, which is still clinically meaningful at higher doses).

Understanding peptide mechanisms is essential for evaluating research claims and choosing appropriate compounds for study. Here are the practical takeaways:

Receptor selectivity determines side effects. Peptides that bind a single receptor type (like ipamorelin, which selectively targets the ghrelin receptor) tend to have cleaner side-effect profiles than those affecting multiple pathways.

Signalling cascades explain dose-response curves. Because peptides work through amplification cascades, small changes in dose can produce disproportionate changes in effect. This is why precise dosing matters more with peptides than with many supplements.

Half-life dictates protocol design. A peptide with a 2-hour half-life requires multiple daily administrations to maintain stable levels, while weekly-dosed peptides like semaglutide provide consistent receptor activation.

Modification affects behaviour. A modified peptide (like CJC-1295 with DAC) may have different pharmacokinetics, receptor binding affinity, and side-effect profiles compared to its unmodified parent molecule. Always check which variant a study used before drawing conclusions.

For a deeper look at receptor pharmacology, see our Receptor Binding & Selectivity science hub article. For practical guidance on specific peptides, explore our individual peptide profiles.